Access the full text.
Sign up today, get DeepDyve free for 14 days.
V. Lin, B. Oak, J. Snider, J. Epstein (2020)
Health-related quality of life (HRQOL) burden in patients with relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL) and non-Hodgkin’s lymphoma (RR-NHL).Journal of Clinical Oncology, 38
M. Schwenkglenks, K. Matter-Walstra (2016)
Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developmentsExpert Review of Pharmacoeconomics & Outcomes Research, 16
U. Research, U. Health (2006)
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidanceHealth and Quality of Life Outcomes, 4
S. Schuster, M. Bishop, C. Tam, E. Waller, P. Borchmann, J. Mcguirk, U. Jäger, S. Jaglowski, C. Andreadis, J. Westin, I. Fleury, V. Bachanova, R. Foley, Joy Ho, S. Mielke, J. Magenau, H. Holte, Serafino Pantano, L. Pacaud, R. Awasthi, J. Chu, Ö. Anak, G. Salles, R. Maziarz (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell LymphomaThe New England Journal of Medicine, 380
S. Nagle, K. Woo, S. Schuster, S. Nasta, E. Stadtmauer, R. Mick, J. Svoboda (2013)
Outcomes of patients with relapsed/refractory diffuse large B‐cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab eraAmerican Journal of Hematology, 88
Julia Ruark, Erin Mullane, Nancy Cleary, Ana Cordeiro, Evandro Bezerra, V. Wu, J. Voutsinas, B. Shaw, K. Flynn, Stephanie Lee, C. Turtle, D. Maloney, J. Fann, M. Bar (2020)
Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor-T Cell Therapy.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
C. Thompson, K. Yost, M. Maurer, C. Allmer, U. Farooq, T. Habermann, D. Inwards, W. Macon, B. Link, A. Rosenthal, J. Cerhan (2018)
Quality of life at diagnosis predicts overall survival in patients with aggressive lymphomaHematological Oncology, 36
(Euroquol.EQ-5D. About EQ-5D. https://euroqol.org/eq-5d-instruments/. Accessed Aug 27, 2021.)
Euroquol.EQ-5D. About EQ-5D. https://euroqol.org/eq-5d-instruments/. Accessed Aug 27, 2021.Euroquol.EQ-5D. About EQ-5D. https://euroqol.org/eq-5d-instruments/. Accessed Aug 27, 2021., Euroquol.EQ-5D. About EQ-5D. https://euroqol.org/eq-5d-instruments/. Accessed Aug 27, 2021.
Yang Liu, S. Barta (2019)
Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatmentAmerican Journal of Hematology, 94
D. Cella, D. Tulsky, G. Gray, B. Sarafian, E. Linn, A. Bonomi, M. Silberman, S. Yellen, P. Winicour, J. Brannon, Karen Eckberg, S. Lloyd, S. Purl, C. Blendowski, M. Goodman, M. Barnicle, I. Stewart, M. McHale, P. Bonomi, E. Kaplan, Samuel Taylor, C. Thomas, J. Harris (2015)
Functional Assessment of Cancer Therapy
R. Chakraborty, S. Sidana, G. Shah, M. Scordo, B. Hamilton, N. Majhail (2019)
Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 25 5
E. Smets, B. Garssen, A. Cull, J. Haes (1996)
Application of the multidimensional fatigue inventory (MFI-20) in cancer patients receiving radiotherapy.British Journal of Cancer, 73
J. Friedberg (2011)
Relapsed/refractory diffuse large B-cell lymphoma.Hematology. American Society of Hematology. Education Program, 2011
(Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input guidance for industry, food and drug administration staff, and other stakeholders [Final guidance]. 2020.)
Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input guidance for industry, food and drug administration staff, and other stakeholders [Final guidance]. 2020.Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input guidance for industry, food and drug administration staff, and other stakeholders [Final guidance]. 2020., Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input guidance for industry, food and drug administration staff, and other stakeholders [Final guidance]. 2020.
J. Abramson, M. Palomba, L. Gordon, M. Lunning, Michael Wang, J. Arnason, A. Mehta, E. Purev, D. Maloney, C. Andreadis, A. Sehgal, S. Solomon, N. Ghosh, T. Albertson, Jacob Garcia, A. Kostić, Mary Mallaney, K. Ogasawara, K. Newhall, Yeonhee Kim, Daniel Li, T. Siddiqi (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyThe Lancet, 396
K Charmaz (1995)
10.4135/9781446221792.n3
National Comprehensive Cancer Network Ò NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Ò . B-Cell Lymphomas
K. Jamani, L. Onstad, M. Bar, P. Carpenter, E. Krakow, R. Salit, M. Flowers, Stephanie Lee (2018)
Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 24 11
G. Lenz, S. Rutherford, A. Davies, P. Zinzani, G. Salles, J. Hasskarl, Sandra Margunato‐Debay, F. Rodrigues, L. Nientker, Janita Balradj, C. Alleman (2018)
The Burden of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Systematic Literature Review (SLR)Blood
R. Nipp, J. Temel (2018)
Harnessing the Power of Patient-Reported Outcomes in OncologyClinical Cancer Research, 24
A. Zelenetz, L. Gordon, J. Abramson, R. Advani, N. Bartlett, P. Caimi, Julie Chang, J. Chavez, B. Christian, L. Fayad, M. Glenn, T. Habermann, Nancy Harris, F. Hernandez-Ilizaliturri, M. Kaminski, C. Kelsey, N. Khan, Susan Krivacic, A. LaCasce, A. Mehta, A. Nademanee, R. Rabinovitch, N. Reddy, E. Reid, K. Roberts, Stephen Smith, Erin Snyder, L. Swinnen, J. Vose, M. Dwyer, Hema Sundar (2019)
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.Journal of the National Comprehensive Cancer Network : JNCCN, 17 6
M. Reilly, A. Zbrozek, E. Dukes (1993)
The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 4
D. Cella, D. Tulsky, G. Gray, B. Sarafian, E. Linn, A. Bonomi, M. Silberman, S. Yellen, P. Winicour, J. Brannon (1993)
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 11 3
Mandi Pratt-Chapman, Afsan Bhadelia (2018)
Patient-Reported Outcomes in Health Economic Decision-Making: A Changing Landscape in Oncology.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 213
(EORTC. Quality of Life. https://qol.eortc.org/. Accessed Aug 27, 2021.)
EORTC. Quality of Life. https://qol.eortc.org/. Accessed Aug 27, 2021.EORTC. Quality of Life. https://qol.eortc.org/. Accessed Aug 27, 2021., EORTC. Quality of Life. https://qol.eortc.org/. Accessed Aug 27, 2021.
R. Warsame, A. D’Souza (2019)
Patient Reported Outcomes Have Arrived: A Practical Overview for Clinicians in Using Patient Reported Outcomes in Oncology.Mayo Clinic proceedings
T. Philip, C. Guglielmi, A. Hagenbeek, Renier Somers, H. Lelie, D. Bron, P. Sonneveld, C. Gisselbrecht, J. Cahn, J. Harousseau, B. Coiffier, P. Biron, F. Mandelli, F. Chauvin (1995)
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.The New England journal of medicine, 333 23
R. Rabin, F. Charro (2001)
EQ-SD: a measure of health status from the EuroQol GroupAnnals of Medicine, 33
C. Lippe, P. Diesen, K. Feragen (2017)
Living with a rare disorder: a systematic review of the qualitative literatureMolecular Genetics & Genomic Medicine, 5
T. Ollila, A. Olszewski (2018)
Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System RecurrenceCurrent Treatment Options in Oncology, 19
N. Aaronson, S. Ahmedzai, B. Bergman, M. Bullinger, A. Cull, N. Duez, A. Filiberti, H. Flechtner, S. Fleishman, J. Haes, S. Kaasa, M. Klee, D. Osoba, D. Razavi, Peter Rofe, S. Schraub, K. Sneeuw, M. Sullivan, F. Takeda (1993)
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.Journal of the National Cancer Institute, 85 5
(National Comprehensive Cancer Network® NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)®. B-Cell Lymphomas. Version 4.2021. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf.)
National Comprehensive Cancer Network® NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)®. B-Cell Lymphomas. Version 4.2021. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf.National Comprehensive Cancer Network® NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)®. B-Cell Lymphomas. Version 4.2021. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf., National Comprehensive Cancer Network® NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)®. B-Cell Lymphomas. Version 4.2021. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf.
(National Institutes of Health. Office of strategic coordination—the common fund. Patient-reported outcomes measurement information system (PROMIS). https://commonfund.nih.gov/promis/index. Accessed Aug 27, 2021.)
National Institutes of Health. Office of strategic coordination—the common fund. Patient-reported outcomes measurement information system (PROMIS). https://commonfund.nih.gov/promis/index. Accessed Aug 27, 2021.National Institutes of Health. Office of strategic coordination—the common fund. Patient-reported outcomes measurement information system (PROMIS). https://commonfund.nih.gov/promis/index. Accessed Aug 27, 2021., National Institutes of Health. Office of strategic coordination—the common fund. Patient-reported outcomes measurement information system (PROMIS). https://commonfund.nih.gov/promis/index. Accessed Aug 27, 2021.
S. Neelapu, S. Tummala, P. Kebriaei, W. Wierda, C. Gutierrez, F. Locke, K. Komanduri, Yi Lin, N. Jain, N. Daver, J. Westin, A. Gulbis, M. Loghin, J. Groot, S. Adkins, Suzanne Davis, K. Rezvani, P. Hwu, E. Shpall (2018)
Chimeric antigen receptor T-cell therapy — assessment and management of toxicitiesNature Reviews Clinical Oncology, 15
E. Zagadailov, M. Fine, A. Shields (2013)
Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers.American health & drug benefits, 6 5
(2013)
Grounded theory.Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses, 22 2
KE Hunt (2008)
10.5858/2008-132-118-DLBLArch Pathol Lab Med, 132
Janice Kim, H. Singh, Kassa Ayalew, K. Borror, Michelle Campbell, L. Johnson, Alyson Karesh, N. Khin, J. Less, J. Menikoff, L. Minasian, S. Mitchell, Elektra Papadopoulos, R. Piekarz, Kevin Prohaska, Susan Thompson, R. Sridhara, R. Pazdur, P. Kluetz (2017)
Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site InspectionsClinical Cancer Research, 24
L. Yáñez, Míriam Sanchez-Escamilla, M. Perales (2019)
CAR T Cell Toxicity: Current Management and Future DirectionsHemaSphere, 3
(2020)
Patient-focused drug development: collecting comprehensive and representative input guidance for industry, food and drug administration staff, and other stakeholders
M. Price, A. Ravelo, M. Sae-Hau, P. Torney, V. Gonzalez, E. Weiss, C. Mansfield, B. Mange, Eydith Ortiz, A. Masaquel, K. Dawson (2019)
Patient-reported disease burden in chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma: Results from a national patient advocacy survey.Journal of Clinical Oncology
F. Hlubocky, K. Webster, J. Beaumont, J. Cashy, D. Paul, A. Abernethy, K. Syrjala, J. Roenn, D. Cella (2013)
A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy – Lymphoma Symptom IndexLeukemia & Lymphoma, 54
(2021)
Review (CSR) 1975–2017
D. Telio, K. Fernandes, Clement Ma, R. Tsang, A. Keating, M. Crump, J. Kuruvilla (2012)
Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factorsLeukemia & Lymphoma, 53
(FACIT. FACT-G. Functional assessment of cancer therapy. https://www.facit.org/measures/FACT-G. Accessed Aug 27, 2021.)
FACIT. FACT-G. Functional assessment of cancer therapy. https://www.facit.org/measures/FACT-G. Accessed Aug 27, 2021.FACIT. FACT-G. Functional assessment of cancer therapy. https://www.facit.org/measures/FACT-G. Accessed Aug 27, 2021., FACIT. FACT-G. Functional assessment of cancer therapy. https://www.facit.org/measures/FACT-G. Accessed Aug 27, 2021.
M. Crump, S. Neelapu, U. Farooq, E. Neste, J. Kuruvilla, J. Westin, B. Link, A. Hay, J. Cerhan, Liting Zhu, S. Boussetta, Lei Feng, M. Maurer, L. Navale, J. Wiezorek, W. Go, C. Gisselbrecht (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.Blood, 130 16
Office of strategic coordination-the common fund. Patient-reported outcomes measurement information system
R. Hays, K. Spritzer, B. Schalet, D. Cella (2018)
PROMIS®-29 v2.0 profile physical and mental health summary scoresQuality of Life Research, 27
K. Lasch, P. Marquis, M. Vigneux, L. Abetz, B. Arnould, M. Bayliss, B. Crawford, K. Rosa (2010)
PRO development: rigorous qualitative research as the crucial foundationQuality of Life Research, 19
Lauren Teras, C. DeSantis, J. Cerhan, L. Morton, A. Jemal, C. Flowers (2016)
2016 US lymphoid malignancy statistics by World Health Organization subtypesCA: A Cancer Journal for Clinicians, 66
A. Chiappella, E. Santambrogio, A. Castellino, M. Nicolosi, U. Vitolo (2017)
Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphomaExpert Review of Hematology, 10
G. Lopez, J. Lacey, A. Christie, Catherine Powers-James, Santhosshi Narayanan, Wenli Liu, L. Cohen (2019)
Patient-Reported Outcomes in Integrative Oncology: Bridging Clinical Care With Research.Cancer journal, 25 5
L. Poll-Franse, S. Oerlemans, A. Brédart, C. Kyriakou, M. Sztankay, S. Pallua, L. Daniëls, C. Creutzberg, K. Cocks, S. Malak, G. Caocci, S. Molica, W. Chie, F. Efficace (2017)
International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemiaQuality of Life Research, 27
A. Gnanasakthy, C. Demuro, M. Clark, E. Haydysch, E. Ma, V. Bonthapally (2016)
Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 16
E. Smets, B. Garssen, B. Bonke, J. Haes (1995)
The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue.Journal of psychosomatic research, 39 3
Jennifer Brudno, J. Kochenderfer (2018)
Chimeric antigen receptor T-cell therapies for lymphomaNature Reviews Clinical Oncology, 15
D. Tholstrup, P. Brown, J. Jurlander, P. jeppesen, M. Groenvold (2011)
Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarilyLeukemia & Lymphoma, 52
M. Poel, Simone Oerlemans, H. Schouten, F. Mols, J. Pruijt, Huub Maas, L. Poll-Franse (2014)
Quality of life more impaired in younger than in older diffuse large B cell lymphoma survivors compared to a normative population: a study from the population-based PROFILES registryAnnals of Hematology, 93
E. Grigor, D. Fergusson, N. Kekre, J. Montroy, H. Atkins, M. Seftel, M. Daugaard, J. Presseau, K. Thavorn, B. Hutton, R. Holt, M. Lalu (2019)
Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.Transfusion medicine reviews, 33 2
D. Cella, Seung Choi, D. Condon, B. Schalet, R. Hays, N. Rothrock, S. Yount, K. Cook, R. Gershon, D. Amtmann, D. DeWalt, P. Pilkonis, A. Stone, K. Weinfurt, B. Reeve (2019)
PROMIS® Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 22 5
C. Brodsky (1968)
The Discovery of Grounded Theory: Strategies for Qualitative ResearchPsychosomatics, 9
H. Tilly, M. Silva, U. Vitolo, A. Jack, M. Meignan, A. López-Guillermo, J. Walewski, M. André, Peter Johnson, M. Pfreundschuh, M. Ladetto (2012)
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 26 Suppl 5
D. Cella, William Riley, A. Stone, N. Rothrock, B. Reeve, S. Yount, D. Amtmann, R. Bode, Daniel Buysse, Seung Choi, K. Cook, R. Devellis, D. DeWalt, J. Fries, R. Gershon, E. Hahn, J. Lai, P. Pilkonis, D. Revicki, M. Rose, K. Weinfurt, R. Hays (2010)
The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008.Journal of clinical epidemiology, 63 11
(Lin V, Oak B, Snider J, Epstein J. Health-related quality of life (HRQOL) burden in patients with relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL) and non-Hodgkin’s lymphoma (RR-NHL) [abstract]. J Clin Oncol. 2020;38:Abstract e20070.)
Lin V, Oak B, Snider J, Epstein J. Health-related quality of life (HRQOL) burden in patients with relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL) and non-Hodgkin’s lymphoma (RR-NHL) [abstract]. J Clin Oncol. 2020;38:Abstract e20070.Lin V, Oak B, Snider J, Epstein J. Health-related quality of life (HRQOL) burden in patients with relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL) and non-Hodgkin’s lymphoma (RR-NHL) [abstract]. J Clin Oncol. 2020;38:Abstract e20070., Lin V, Oak B, Snider J, Epstein J. Health-related quality of life (HRQOL) burden in patients with relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL) and non-Hodgkin’s lymphoma (RR-NHL) [abstract]. J Clin Oncol. 2020;38:Abstract e20070.
(Kelly JL, Pandya C, Friedberg JW, Mohile SG. Health-related quality of life in older patients following diffuse large B-cell lymphoma (DLBCL) diagnosis [abstract]. Blood. 2012;120:Abstract 4287.)
Kelly JL, Pandya C, Friedberg JW, Mohile SG. Health-related quality of life in older patients following diffuse large B-cell lymphoma (DLBCL) diagnosis [abstract]. Blood. 2012;120:Abstract 4287.Kelly JL, Pandya C, Friedberg JW, Mohile SG. Health-related quality of life in older patients following diffuse large B-cell lymphoma (DLBCL) diagnosis [abstract]. Blood. 2012;120:Abstract 4287., Kelly JL, Pandya C, Friedberg JW, Mohile SG. Health-related quality of life in older patients following diffuse large B-cell lymphoma (DLBCL) diagnosis [abstract]. Blood. 2012;120:Abstract 4287.
(SEER Cancer Statistics Review (CSR) 1975–2017. National Cancer Institute—National Institute of Health. https://seer.cancer.gov/statfacts/html/dlbcl.html. Accessed Jan 2021.)
SEER Cancer Statistics Review (CSR) 1975–2017. National Cancer Institute—National Institute of Health. https://seer.cancer.gov/statfacts/html/dlbcl.html. Accessed Jan 2021.SEER Cancer Statistics Review (CSR) 1975–2017. National Cancer Institute—National Institute of Health. https://seer.cancer.gov/statfacts/html/dlbcl.html. Accessed Jan 2021., SEER Cancer Statistics Review (CSR) 1975–2017. National Cancer Institute—National Institute of Health. https://seer.cancer.gov/statfacts/html/dlbcl.html. Accessed Jan 2021.
(WPAI References. http://www.reillyassociates.net/WPAI_References5.html. Accessed Aug 27, 2021.)
WPAI References. http://www.reillyassociates.net/WPAI_References5.html. Accessed Aug 27, 2021.WPAI References. http://www.reillyassociates.net/WPAI_References5.html. Accessed Aug 27, 2021., WPAI References. http://www.reillyassociates.net/WPAI_References5.html. Accessed Aug 27, 2021.
(FACT-Lym Survey. https://8beeac51-650b-405c-97a4-0987e05a41f1.filesusr.com/ugd/626819_0df9df363a394774af45e4cabff63ffc.pdf. Accessed Aug 27, 2021.)
FACT-Lym Survey. https://8beeac51-650b-405c-97a4-0987e05a41f1.filesusr.com/ugd/626819_0df9df363a394774af45e4cabff63ffc.pdf. Accessed Aug 27, 2021.FACT-Lym Survey. https://8beeac51-650b-405c-97a4-0987e05a41f1.filesusr.com/ugd/626819_0df9df363a394774af45e4cabff63ffc.pdf. Accessed Aug 27, 2021., FACT-Lym Survey. https://8beeac51-650b-405c-97a4-0987e05a41f1.filesusr.com/ugd/626819_0df9df363a394774af45e4cabff63ffc.pdf. Accessed Aug 27, 2021.
SS Neelapu (2017)
10.1056/NEJMoa1707447N Engl J Med, 377
S. Sidana, G. Thanarajasingam, J. Griffin, C. Thompson, M. Burtis, R. Warsame, J. Paludo, A. Cheville, M. Gertz, A. Dispenzieri, J. Villasboas, S. Ansell, S. Rajkumar, K. Yost, N. Bennani, M. Siddiqui, Yi Lin, Shaji Kumar, A. Dueck (2019)
Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of LifeBlood
Daniel Lee, B. Santomasso, F. Locke, A. Ghobadi, C. Turtle, Jennifer Brudno, M. Maus, Jae Park, E. Mead, S. Pavletic, W. Go, L. Eldjerou, R. Gardner, N. Frey, K. Curran, K. Peggs, M. Pasquini, J. Dipersio, M. Brink, K. Komanduri, S. Grupp, S. Neelapu (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 25 4
(Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. 2009. p. 1–35.)
Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. 2009. p. 1–35.Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. 2009. p. 1–35., Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. 2009. p. 1–35.
A. Ng (2007)
Diffuse large B-cell lymphoma.Seminars in radiation oncology, 17 3
IntroductionChimeric antigen receptor T-cell (CAR T) therapy offers a potentially curative option for patients with relapsed and refractory hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL). Patient-reported experiences with CAR T therapy are limited and have not been well characterized. The purpose of this qualitative study was to explore patient descriptions of key domains of health-related quality of life (HRQoL) in DLBCL patients treated with CAR T therapy.MethodsA targeted literature review was initially conducted to inform the development of the interview guide comprising predetermined open-ended questions. Two focus groups were conducted with a total of 18 patients with DLBCL identified from patient advisory boards. Focus group sessions were recorded and transcribed verbatim. MAXQDA 18.2.0 qualitative data analysis software was utilized to facilitate a constant-comparative coding process to identify key concepts.ResultsEight domain impairments (social functioning, emotional functioning, fatigue, physical functioning, cognitive functioning, role functioning, sleep, and pain/discomfort) were identified from the qualitative analysis and endorsed by DLBCL patients treated with CAR T. Compared with before CAR T therapy, patients reported increased impairment in every domain during or immediately after CAR T therapy. This impairment improved for each domain 6 months after CAR T therapy except for pain/discomfort. Compared with before CAR T therapy, improvement in impairment for each domain was observed 6 months after CAR T therapy except for fatigue, sleep, and pain/discomfort.ConclusionThis study provides meaningful information regarding the impact of CAR T therapy on HRQoL in patients with DLBCL throughout their treatment journey. Health care professionals and investigators can utilize these data in examining existing patient-reported outcome (PRO) measures that are used in DLBCL clinical trials and to better understand the needs of DLBCL survivors.
Oncology and Therapy – Springer Journals
Published: Jun 1, 2022
Keywords: Chimeric antigen receptor (CAR) T-cell therapy; Diffuse large B-cell lymphoma; DLBCL; Health-related quality of life; HRQoL; Non-Hodgkin lymphoma; Patient-reported outcome
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.